Drugs / SYN008
last change Jun 2023 re-read 2 minutes ago

SYN008

Developed for
chronic urticaria
Investigated by
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04944602 Jul 2021 → Mar 2023 chronic urticaria CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SYN008 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04944602
Route Subcutaneous “SYN008 300 mg s.c.” NCT04944602